The company is leveraging its material and polymer expertise to expand into the life sciences industry in the two major industry categories of bioprocessing and diagnostic and research products.
“With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”
CrownBio clients will be now able to manage their internal patient-derived xenograft (PDX) portfolio on the model of CrownBio’s bespoke HuBase technology platform.
CrownBio intends to expand characterization, including next generation sequencing, of the models, and ultimately to develop new models resistant to current clinical therapies.
The KBI Biopharma agreement provides that KBI Biopharma will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial...
Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02.
This expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants, and additional announcements on new models and capabilities at its UK facilities
To acquire biologics manufacturing facility and capabilities from XOMAAcquires rights to Selexis cell line development technology. Purchases an exclusive license to a Phage Display library from Iontas
